Toxicity profile of interferon alfa-2b in children: A prospective evaluation

Journal of Pediatrics

Volumn 135, Issue 6, 1999, Pages 782-785

  Dubois, Josée ^a   Hershon, Linda ^a   Carmant, Lionel ^a   Bélanger, Stacey ^a   Leclerc, Jean Marie ^a   David, Michèle ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PREDNISONE; RECOMBINANT ALPHA2B INTERFERON;

ARTICLE; BLOOD TOXICITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEMANGIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SKIN TOXICITY;

EID: 0033504699     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(99)70104-6     Document Type: Article

References (14)

1. 1. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Safety 1994;10: 115-50.
2. 2. Vesikari T, Nuutila A, Cantell K. Neurologic sequelae following Interferon therapy of juvenile laryngeal papilloma. Acta Paediatr Scand 1988:77:619-22.
3. 3. Barlow CF, Priefae CJ, Mulliken JB, Barnes PD, MacDonald D, Folkman J, Ezekowitz RAB. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr 1998;132:527-30.
4. 4. World Health Organisation. WHO handbook for reporting results of cancer treatment. Geneva: WHO publications; 1979. p. 38.
5. 5. Barlow C, Priebe CJ, Mulliken JB, Barnes P. Neurotoxicity in the treatment of hemangiomas with interferon alpha 2A. Tenth International Workshop on Vascular Anomalies, Rome, June 1996.
6. 6. Orchard PJ, Smith CM, Woods WG, Day DL, Dehner LP, Shapiro R. Treatment of haemangioendotheliomas with alpha Interferon. Lancet 1989;2:565-7.
7. 7. White CW, Wolf SJ, Korones DN, Sondheimer HM, Tosi MF, Yu A. Treatment of childhood angiomatous diseases with recombinant Interferon alfa-2a. J Pediatr 1991;118:59-66.
8. 8. Ezekowitz RAB, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infanv cy. N Engl J Med 1992:326:1456-63.
9. 9. Chang E, Boyd A, Nelson CC, Crowley D, Law T, Keough KM, et al. Successful treatment of infantile hemangiomas with interferon-α-2b. J Pediatr Hematol Oncol 1997;19:237-44.
10. 10. Tamayo L, Ortiz DM, Orozco-Covarrubias L, Duran-McKinster C, Mora MA, Avila E, et al. Therapeutic efficacy of Interferon alfa-2b in infants with life-threatening giant hemangiomas. Arch Dermatol 1997;133:1567-71.
11. 11. Hastings MM, Milot J, Barsoum-Homsy M, Hershon L, Dubois J, Leclerc JM. Recombinant interferon alfa-2b in the treatment of vision-threatening capillary hemangiomas in childhood. J AAPOS 1997:1:226-30.
12. 12. Torre D, Tambini R. Interferon-α therapy for chronic hepatitis B in children: a meta-analysis. CID 1996;23:131-7.
13. 13. Iorio R, Pensati P, Botta S, Moschella S, Impagliazzo N, Vajro P, Vegnente A. Side effects of alpha-interferon therapy and impact on health-related quality of life in children with chronic viral hepatitis. Pediatr Infect Dis J 1997:16:984-90.
14. 14. Ezekowitz A, Mulliken J, Folkman J. Additional corrections: interferon for hemangiomas of infancy. N Engl J Med 1995:333:595-6.